For the first time in decades, Canadian researchers are probing the potential of a psychedelic drug – ecstasy – for use in psychotherapy in a clinical trial approved by Health Canada. The Multidisciplinary Association for Psychedelic Studies (MAPS), is investigating the use of MDMA, the pure form of the party drug ecstasy, to assist therapy sessions for people with treatment-resistant post-traumatic stress disorder (PTSD). The early research coming from this team has shown promise in treating those who suffer from some of the most challenging forms of PTSD. Filling a gap Currently available PTSD treatments have little effect on […]

Continue Reading...